Production and quality control of [90Y]DOTATOC for treatment of metastatic neuroendocrine tumors: Results of 85 syntheses

Giorgio Biasiotto, Francesco Bertagna, Isabella Zanella, Ugo Biasiotto, Giordano Savelli, Luigi Caimi, Giovanni Bettinsoli, Raffaele Giubbini, Marco Chinol

Research output: Contribution to journalArticlepeer-review


The aim of this paper was to describe the optimized labeling protocol and quality control measures used in the production of [90Y]DOTATOC, starting from three different radioactivity levels to treat one, two, or three patients per therapeutic session. We investigated three different starting radioactivity levels. For the low radioactivity preparation we used 5138±280 MBq of [90Y] isotope, for the medium radioactivity preparation we used 8893±900 MBq, and for the high radioactivity preparation we used 11250±715 MBq. The radiochemical purity levels for the low radioactivity preparation, medium radioactivity preparation, and high radioactivity preparation were 99.95±0.09, 99.84±0.34, and 99.84±0.53%, respectively, and the radiochemical yields of the labeling procedures were 77.52±1.28, 75.53±3.72, and 78.00±3.20%, respectively. Media fill validation of the process was performed, and the parameters of pH, bacterial endotoxins, sterility, and osmolality were tested at process control. All radiopharmaceutical preparations satisfied the predetermined specifications fixed in our protocol regardless of the starting radioactivity level. The validation of the method guaranteed the safety and quality of the final products, contributing to providing the basis for constructing an informative and successful clinical trial.

Original languageEnglish
Pages (from-to)265-270
Number of pages6
JournalNuclear Medicine Communications
Issue number3
Publication statusPublished - Mar 2013


  • Neuroendocrine tumors
  • Quality controls
  • Radiopharmaceutical

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'Production and quality control of [90Y]DOTATOC for treatment of metastatic neuroendocrine tumors: Results of 85 syntheses'. Together they form a unique fingerprint.

Cite this